192369-93-0 Usage
General Description
5-(Bromomethyl)-1H-indazole hydrobromide is a chemical compound with the molecular formula C8H8Br2N2. It is a derivative of indazole, a heterocyclic aromatic organic compound. 5-(Bromomethyl)-1H-indazole hydrobromide contains a bromomethyl group, which is a methyl group substituted with a bromine atom. As a hydrobromide, it is a salt form of the compound, with the bromide ion being the counterion. 5-(Bromomethyl)-1H-indazole hydrobromide has potential applications in organic synthesis and pharmaceutical research, as indazoles and their derivatives have been studied for their various biological activities, including their potential as anticancer, antiviral, and antibacterial agents. However, as a brominated compound, it is important to handle and use it with caution, as bromine compounds can be toxic and corrosive.
Check Digit Verification of cas no
The CAS Registry Mumber 192369-93-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,2,3,6 and 9 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 192369-93:
(8*1)+(7*9)+(6*2)+(5*3)+(4*6)+(3*9)+(2*9)+(1*3)=170
170 % 10 = 0
So 192369-93-0 is a valid CAS Registry Number.
192369-93-0Relevant articles and documents
Non-covalent thrombin inhibitors
-
, (2008/06/13)
The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biologic
Thrombin inhibitors having a lactam at P3
-
, (2008/06/13)
The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.